For the millions living with chronic kidney disease, the disease itself is rarely the only adversary. Understanding how the burden of coexisting conditions compounds kidney outcomes reframes CKD management from organ-focused care to a whole-person systemic challenge — and this large UK cohort study quantifies that burden with unusual precision.
Drawing on 2,996 adults across 16 nephrology centres in the NURTuRE-CKD prospective cohort, every single participant entered the study with at least one comorbidity beyond CKD, meaning true multiple long-term condition (MLTC) burden was universal in this referred population. The median comorbidity count sat at three conditions at baseline, ranging as high as 19. Hypertension, pain, obesity, hyperuricaemia, diabetes, sarcopenia, and cardiovascular disease dominated the baseline profile. Over a median follow-up of roughly 17 months, pain emerged as the most rapidly accumulating new condition (14% of participants), followed by anxiety and depression (11%) and cognitive impairment (6%) — the last being particularly notable given how infrequently it is screened in nephrology settings. The study tracked all-cause mortality, progression to eGFR below 15 mL/min/1.73m² or kidney replacement therapy, and health-related quality of life via the EQ-5D-5L instrument.
This study's strength lies in its multicentre design and the systematic inclusion of neuropsychiatric and cognitive outcomes alongside traditional clinical endpoints — a methodological step that most CKD cohorts omit. The rapid accrual of anxiety, depression, and cognitive impairment within less than 18 months underscores that mental health deterioration in CKD is not a late-stage phenomenon but an early and compounding one. A key limitation is the relatively short median follow-up and the referral-centre bias, which likely overrepresents more complex patients. Still, the finding that comorbidity burden is essentially universal — not a subgroup concern — should shift clinical framing: multimorbidity in CKD is the norm, not the exception, and monitoring frameworks built around eGFR alone are structurally incomplete.